Basic Genomics
Private Company
Total funding raised: $2.3M
Overview
Basic Genomics is a Stockholm-based private company developing a proprietary synthetic long-read RNA sequencing platform called RNA BaseCode™. The technology bridges the gap between the practicality of short-read sequencing and the detailed, full-transcript information of long-read sequencing by using unique molecular barcodes to assemble short reads into accurate synthetic long reads. This enables researchers to comprehensively analyze RNA isoforms from low-input samples, which is critical for understanding gene function in health and disease. The company appears to be in an early commercial stage, offering both kits and services directly to the research market.
Technology Platform
RNA BaseCode™: A proprietary synthetic long-read RNA sequencing technology that uses unique molecular barcodes during reverse transcription to assemble standard short-read data into accurate, full-length transcript sequences (isoforms).
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Basic Genomics competes in the niche between high-throughput short-read sequencing (dominated by Illumina) and native long-read sequencing (dominated by PacBio and Oxford Nanopore). It differentiates on accuracy, cost-effectiveness for long-read data, and workflow simplicity. Key competitors include other synthetic long-read methods (e.g., 10x Genomics Linked Reads, Loop Genomics) and bioinformatics tools for isoform reconstruction from short reads.